Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | IDH2 | P48735 | 7/20 | 0.48 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533275 | 0.93 | PTGS2 (0.51) | JAK3LCKPTGS2IDH2CAMK1D | |
| SCHEMBL5380852 | 0.91 | PTGS2 (0.61) | JAK3LCKPTGS2IDH2LMNA | |
| SCHEMBL5380832 | 0.91 | PTGS2 (0.61) | JAK3LCKPTGS2IDH2LMNA | |
| SCHEMBL5385107 | 0.90 | JAK3 (0.46) | JAK3LCKPTGS2CAMK1DLRRK2 | |
| SCHEMBL5448356 | 0.90 | JAK3 (0.46) | JAK3LCKPTGS2CAMK1DLRRK2 | |
| SCHEMBL5383894 | 0.88 | PTGS2 (0.50) | JAK3LCKPTGS2CAMK1DLRRK2 | |
| SCHEMBL5391943 | 0.88 | IDH2 (0.51) | PTGS2IDH2LMNA | |
| SCHEMBL5388839 | 0.86 | PTGS2 (0.46) | JAK3LCKPTGS2CAMK1DLRRK2 | |
| SCHEMBL5383940 | 0.85 | PTGS2 (0.47) | JAK3LCKPTGS2CAMK1DLRRK2 | |
| SCHEMBL5392155 | 0.83 | JAK3 (0.42) | JAK3LCKPTGS2IDH2CAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | JAK3 758/4885LCK 1653/4885PTGS2 4416/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | JAK3 433/4885LCK 3115/4885PTGS2 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.